Meeting
2021 Gastrointestinal Cancers Symposium
Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival.
Presenter
Eric Van Cutsem, PhD, MD
University Hospital Gasthuisberg and University of Leuven
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Rapid Oral Abstract Session
Session Title
Rapid Abstract Session: Anal and Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02743221
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 14)
DOI
10.1200/JCO.2021.39.3_suppl.14
Abstract #
14
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Speaker: Stephanie Lheureux, MD, PhD
Videos & Slides
2023 ASCO Annual Meeting
Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study.
Speaker: Thierry Andre, MD
Videos & Slides
2023 ASCO Annual Meeting
FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.
Speaker: Carlotta Antoniotti, MD, PhD